Pharmafile

APRIL 11, 2024

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share, totaling an approximate $4.9bn. The transaction has been approved by both companies’ board of directors and is expected to close later in the second quarter of 2024.

Immunization 59

Immunization Immunity 59

Drug Patent Watch

DECEMBER 9, 2024

Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immune response, can be highly variable and impact the safety and efficacy of the drug. 2024, June 19). 2024, May 17). References Bilea, A. Overcoming Regulatory Hurdles in the Development of Biosimilars. link] KBDNA.

Biosimilars 97

Biosimilars Immunity Immunization 97

Digital Pharmacist

AUGUST 21, 2023

As we gear up for the upcoming flu season of 2023-2024, it’s important to reflect on the lessons of the previous year , and understand how the coming year may look different. 2023 Flu Vaccination Changes As we look at the 2023-2024 flu season, what’s new for this year? According to the CDC, in the 2023-2024 season, the U.S.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Express Pharma

NOVEMBER 28, 2024

Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumour cells (5). Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). References Ravindranathan S, Wang X, et al. Nat Med 27, 1536–1543 (2021).

Chemotherapy 111

Chemotherapy Immunity Immunization 111

pharmaphorum

APRIL 10, 2024

billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA nephropathy (IgAN). It is the largest acquisition in the biopharma sector so far in 2024. In another departure from its focus on genetic medicines, Vertex Pharma has agreed a $4.9

Immunity 105

Immunity Immunization 105

Express Pharma

JUNE 9, 2024

4) The regulatory application was supported by positive results from a phase III trial [NCT05590403] (5) evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions.

Vaccines 111

Vaccines Immunity Immunization Diabetes 111

BioPharma Dive

JULY 9, 2024

The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.

Immunity 65

Immunity Immunization 65

Express Pharma

NOVEMBER 21, 2024

Zai Lab and argenx have reportedly received the approval on 11 November 2024, making China the first country in the Asia-Pacific (APAC) region to authorise this treatment. Additionally, it is approved in the EU for gMG and in Japan for gMG and primary immune thrombocytopenia (ITP) under brand names Vyvgart and Vyvdura.

Immunity 96

Immunity Immunization 96

European Pharmaceutical Review

MAY 14, 2024

Takeda and AC Immune SA have agreed a global option and license agreement for a potential first-in-class Abeta-targeting active immunotherapy for Alzheimer’s. AC Immune’s related immunotherapies targeting Abeta are part of the deal, including the Alzheimer’s treatment ACI-24.060.

Immunity 97

Immunity Immunization Drug Development 97

Express Pharma

SEPTEMBER 30, 2024

Healthcare professionals widely recognise the microbiome’s vital contributions to digestion, immune function, and overall well-being. The overwhelming consensus underscores the microbiome’s significant impact on key aspects of human health, including digestion, immune function, and disease resistance.

Immunity 105

Immunity Immunization 105

Pharmacy Times

SEPTEMBER 13, 2023

The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.

Vaccines 55

Vaccines Immunity Immunization 55

Pharmacy Times

SEPTEMBER 25, 2023

For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season.

Vaccines 59

Vaccines Immunity Immunization 59

The Thyroid Pharmacist

DECEMBER 29, 2023

I am hoping to feel more settled in 2024. I am wrapping up some projects in early 2024 and I am carving out more time for myself and my own healing. Adaptogens may also be anti-inflammatory, neuroprotective, and supportive of a healthy immune function. Does Adrenal Fatigue Exist? Gut Recovery Program (est.

Adverse Reactions 72

Adverse Reactions Immunity Immunization Diabetes 72

European Pharmaceutical Review

DECEMBER 18, 2023

Developed in partnership with the University of Copenhagen and Denmark’s Statens Serum Institut , the Foundation says this the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself. Both NCVI and NVAC will be headed by a new NIVI Executive Director/CEO, to be announced in 2024.

Vaccines 105

Vaccines Immunity Immunization 105

Digital Pharmacist

DECEMBER 20, 2023

A few types of free screenings you could offer: Wellness exams Full cholesterol panels Blood pressure and glucose screenings Health screenings also offer a jumping-off point for promoting other healthcare services, such as senior immunizations for conditions like shingles and pneumonia, or flu shots.

Communication 98

Communication Immunity Immunization 98

Express Pharma

OCTOBER 16, 2024

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments, “The COVID-19 pandemic highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing- factors that drove the success of mRNA-based COVID-19 vaccines.” billion in July 2024.

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

Express Pharma

JULY 1, 2024

AstraZeneca stated on July, 1 2024, that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated assessment.

Vaccines 103

Vaccines Immunity Immunization 103

Pharmacy Times

JANUARY 22, 2024

The schedule includes RSV vaccination, along with updated versions of the COVID-19 vaccine.

Vaccines 50

Vaccines Immunity Immunization 50

European Pharmaceutical Review

JUNE 28, 2024

The post <em>European Pharmaceutical Review </em> Issue 3 2024 appeared first on European Pharmaceutical Review.

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52

European Pharmaceutical Review

SEPTEMBER 12, 2023

The immunotherapy activating tumour specific T-cells, off-the-shelf, neoepitope-based vaccine Tedopi ® was evaluated in HLA-A2 positive patients with advanced or metastatic NSCLC in monotherapy in third line NSCLC with secondary resistance to immune checkpoint inhibitors, in the Phase III clinical trial Atalante-1. percent versus 27.5

Vaccines 98

Vaccines Chemotherapy Immunity Immunization 98

European Pharmaceutical Review

JUNE 13, 2024

In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa. In May 2024, Ocugen announced the second cohort (medium dose) completed dosing in the dose-escalation phase. Tell us about Ocugen’s lead programme, OCU400.

Immunity 145

Immunity Immunization Vaccines 145

Express Pharma

AUGUST 27, 2024

The research on this vaccine was published in the journal Nature Communications on August 26, 2024. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over. It is still killing around 1,700 people a week around the world.

Vaccines 104

Vaccines Immunity Immunization Communication 104

Putting Patients First Blog

DECEMBER 12, 2023

Jeff Todd , President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024. Jeff Todd , President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024.

Diabetes 56

Diabetes Immunity Immunization 56

Express Pharma

NOVEMBER 13, 2024

Bristol Myers Squibb and Cabaletta Bio are set to present promising Phase I data on CD19-directed CAR T therapies for severe, refractory lupus at the American College of Rheumatology 2024. Edits made by EP News Bureau The post CAR T cell therapies to promote drug-free remission in lupus care appeared first on Express Pharma.

Immunity 105

Immunity Immunization 105

Pharmacy Times

DECEMBER 11, 2024

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Immunity 52

Immunity Immunization Chemotherapy 52

Putting Patients First Blog

FEBRUARY 20, 2024

While there are no cures for CIDP or MMN, there are fortunately some effective therapies, most notably immune globulin (IG), which replaces the malfunctioning antibodies with healthy antibody proteins isolated from donated human plasma. Patients in the demonstration on average received treatment 2.26

Immunity 85

Immunity Immunization 85

European Pharmaceutical Review

JANUARY 11, 2024

Ustekinumab biologic Once the European Supplementary Protection Certificate (SPC) for Stelara expires in July 2024, this will open up market entry as soon as possible for Uzpruvo, now that it is approved in Europe” Ustekinumab is a human IgG1κ monoclonal antibody (mAb).

Biosimilars 115

Biosimilars Immunity Immunization 115

Pharma Times

DECEMBER 19, 2023

Neutrophils are a type of white blood cell that helps the immune system fight infections and heal injuries. ” Researchers who are interested in participating in this research are encouraged to respond to this international call for application by submitting a project proposal via the BioMed X Career Space before 18 February 2024.

Immunity 123

Immunity Immunization 123

European Pharmaceutical Review

JANUARY 2, 2024

The transaction is expected to close in the first quarter of 2024, subject to certain closing conditions. Data showed that 18 percent of industry professionals believed this to be the case, with personalised medicine predicted as the top trend in 2024, according to 16 percent of the respondents.

Immunity 98

Immunity Immunization 98

Big Molecule Watch

SEPTEMBER 3, 2024

Approval of Celltrion’s Ustekinumab Biosimilar in the EU: On August 26, 2024, Celltrion announced that the European Commission (EC) granted approval for STEQEYMA, formerly known as CT-P43, a biosimilar of STELARA (ustekinumab), for the treatment of several chronic inflammatory conditions.

Biosimilars 69

Biosimilars Immunity Immunization 69

pharmaphorum

SEPTEMBER 27, 2022

The principal is much the same as in checkpoint inhibitor treatment: preventing the cancer cells from evading detection by the body’s immune system and highlighting them for destruction by T cells. The ability for cancer cells to create this suppressive tumour microenvironment (TME) allows them to avoid detection by the immune system.

Vaccines 97

Vaccines Immunity Immunization 97

European Pharmaceutical Review

JUNE 25, 2024

This indicates that the treatment can help to preserve important immune functions in the body. This one-year data for OCREVUS SC was presented in April this year at the 2024 American Academy of Neurology (AAN) Annual Meeting. percent, over 48 weeks of treatment.

Immunity 111

Immunity Immunization 111

European Pharmaceutical Review

APRIL 10, 2024

It also suggests the potential to use NX-5948 as a therapeutic option for immune indications with CNS involvement such as multiple sclerosis.” These data were presented at the 2024 American Association for Cancer Research (AACR) 2024 Annual Meeting.

Immunity 97

Immunity Immunization 97

European Pharmaceutical Review

AUGUST 9, 2023

The pharmaceutical company announced that it plans to submit to global health authorities in 2024. There were 470 participants in the REMIX-1 study. In REMIX-2, the clinical trial enrolled 455 participants with CSU.

Immunity 94

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 94

European Pharmaceutical Review

JANUARY 30, 2024

Pembrolizumab targets a “checkpoint” pathway that is key in enabling cancer cells to avoid being destroyed by the immune system. As a result, the immunotherapy drug supports the immune system’s T cells fight tumours, the researchers highlighted. We showed pembrolizumab extends survival. It does not only delay recurrence.”

Immunity 98

Immunity Immunization 98

European Pharmaceutical Review

OCTOBER 25, 2024

the biologic has the potential to deliver anti-tumour responses in the majority of patients with ES-SCLC” The ongoing Phase I trial is assessing the antibody-drug conjugate both as a single treatment and as a combination therapy together with the immune checkpoint inhibitor atezolizumab.

Chemotherapy 97

Chemotherapy Compounding Immunity Immunization 97

Putting Patients First Blog

OCTOBER 9, 2024

Guest Blog: World Sight Day 2024 Shines a Global Light on Children’s Eye Care October 9, 2024 Jeff Todd, President and CEO, Prevent Blindness At Prevent Blindness , our primary focus is on eye health in the United States. This is why the IAPB has devoted World Sight Day 2024 to the youngest among us.

Immunity 40

Immunity Immunization 40